Komori
Techno Medica (6678) · PolicyReframedLatest Share Issuance and Disposal (2026-07-01): "Advanced"

Executive Compensation Scheme Focused on Enhancing Corporate Value and Sharing Value with Shareholders

First written in FY2018. 8 of 11 entries say "Advanced", first in FY2019. Latest entry: 2026-07-01.

11entries
9years
1from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseAdvancedFY2021 – FY20252018: 120182019: 320192020: 120202021: 120212022: 120222023: 020232024: 120242025: 120252026: 22026
Same theme, other companies
Medium- to Long-Term Incentives Through Equity Compensation Plans for Directors and EmployeesA theme 669 companies write about · 0 as a headwind · 692 as a tailwind
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 192 companies compared. The sentences above are computed from all 192.Comparing 200 of the theme's 692 threads.
Full recordFilings, disclosures and news, newest first
  1. 2026-07-01AdvancedShare Issuance and Disposal

    「At a meeting of the Board of Directors held on 9 May 2018, the company resolved to introduce a restricted stock compensation plan for its directors, excluding directors who are Audit and Supervisory Committee members and outside directors, with the purpose of providing ongoing incentives to increase shareholder value during their terms of office, thereby achieving sustained growth in the company's medium- to long-term corporate value and promoting greater value sharing with shareholders.」

    The statement specifies a new allotment under the restricted stock compensation plan, with 24 July 2026 as the payment date. The plan aims to increase shareholder value and sustained medium- to long-term corporate value and to promote value sharing with shareholders.
  2. FY2026ReframedAnnual report

    「From fiscal 2026, the Company revised the indicators used to evaluate company-wide performance. Operating profit had previously been used as the evaluation indicator, but from the current fiscal year, profit before income taxes is being applied to reflect final earning power, including financial activities as well as core operations. The amount is calculated by multiplying profit before income taxes by the points determined internally and a coefficient for each position.」

    The evaluation indicator for short-term performance-linked compensation was changed from operating profit to profit before income taxes, and the calculation method was revised to reflect final earning power, including financial activities.
  3. FY2025AdvancedAnnual report

    「Operating profit for the previous fiscal year × 200 shares × position-based coefficient」

    For the restricted stock compensation program revised from fiscal 2023, the Company disclosed the method of calculating the number of shares granted based on operating profit for the previous fiscal year, 200 shares and a position-based coefficient, as well as compensation expense of ¥36.243 million for the current fiscal year.
  4. FY2024AdvancedAnnual report

    「In addition, from fiscal 2023 (the fiscal year ending March 2024), the Company revised its restricted stock compensation program to further share value with its directors and shareholders and to promote the sustainable enhancement of corporate value. Specifically, the number of Company shares granted to directors is calculated by multiplying operating profit for the previous fiscal year by the number of shares per unit of the performance indicator determined internally and by a position-based coefficient, thereby increasing the linkage to performance.」

    From fiscal 2023, the Company revised its restricted stock compensation program and disclosed that the mechanism for calculating the number of shares granted based on operating profit for the previous fiscal year and a position-based coefficient has reached the implementation stage.
  5. FY2022AdvancedAnnual report

    「In addition, from fiscal 2022, the Company revised its stock compensation program to further share value with its directors and shareholders and to promote the sustainable enhancement of corporate value. Specifically, the number of Company shares granted to directors is calculated by multiplying operating profit for the previous fiscal year by the number of shares per unit of the performance indicator determined internally and by a position-based coefficient, thereby increasing the linkage to performance.」

    From fiscal 2022, the stock compensation program was revised to calculate the number of shares granted based on operating profit for the previous fiscal year and a position-based coefficient.
  6. FY2021AdvancedAnnual report

    「At a meeting of the Board of Directors held on 3 February 2021, the Company resolved its policy for determining the details of individual compensation and other benefits for directors.」

    The Board of Directors formally approved the policy for determining individual compensation and specified the structure and calculation methods for fixed compensation, short-term performance-linked compensation linked to operating profit, and restricted stock compensation.
  7. FY2020ReframedAnnual report

    「In addition, performance-based target achievement bonuses and fixed payments to full-time Audit and Supervisory Committee members have been discontinued from bonuses paid in July 2020.」

    While maintaining the restricted stock compensation program aimed at enhancing corporate value and sharing value with shareholders, the Company discontinued target achievement bonuses and fixed payments to full-time Audit and Supervisory Committee members from payments made in July 2020, changing the composition of executive compensation.
  8. FY2020-Q2AdvancedAnnual report

    「Accordingly, the provision for directors' retirement benefits was fully reversed, and the unpaid portion of the discontinued payment amount, ¥35.598 million excluding amounts already paid, is presented under Other non-current liabilities (long-term accounts payable).」

    In connection with the abolition of the retirement bonus program for directors, the provision for directors' retirement benefits was fully reversed, and the unpaid amount of ¥35.598 million is presented as long-term accounts payable. The accounting treatment associated with abolishing the program has moved to the implementation stage.
  9. FY2020-Q1AdvancedAnnual report

    「At the 32nd Annual General Meeting of Shareholders held on 26 June 2019, the Company resolved to make discontinued payments associated with abolishing the retirement bonus program for directors and to grant retirement bonuses to retiring directors.」

    At the 32nd Annual General Meeting of Shareholders, the abolition of the retirement bonus program for directors, together with discontinued payments associated with the abolition and the granting of retirement bonuses to retiring directors, was approved. Specific changes to the executive compensation program have moved to the implementation stage.
  10. FY2019AdvancedAnnual report

    「To ensure transparency and objectivity in determining compensation amounts, the Company has established a Compensation and Nomination Advisory Committee and determines compensation amounts after prior deliberation by the committee. During the fiscal year, the committee met 4 times and, after discussing appropriate levels of executive compensation and other matters, submitted recommendations for specific compensation amounts.」

    The Compensation and Nomination Advisory Committee met 4 times during the fiscal year, and the process for determining executive compensation, including restricted stock compensation, is being operated.
  11. FY2018First statedAnnual report

    「The Company has introduced a restricted stock compensation program for directors, excluding directors who are Audit and Supervisory Committee members, to provide incentives for the sustainable enhancement of corporate value and further share value with shareholders. The specific allocation to each eligible director is to be determined by the Board of Directors.」

    Restricted stock compensation is positioned as an executive compensation program for the sustainable enhancement of corporate value and sharing value with shareholders, and a Compensation (Nomination) Advisory Committee has been established to ensure transparency and objectivity in compensation amounts.
Moved together

"Achieving Stable Growth in Net Sales and a 20% Ordinary Profit Margin on Net Sales" moved the same way as this thread, in the same document, in 8 of its 11 moves.

866655★123456
  1. ★This thread
  2. 1Achieving Stable Growth in Net Sales and a 20% Ordinary Profit Margin on Net Sales8×
  3. 2Disposal of Treasury Shares as Restricted Stock Compensation6×
  4. 3Reduced dependence on blood collection tube preparation equipment through the expansion of specimen testing equipment6×
  5. 4Expansion of Recurring Sales through Related Consumables and Maintenance Services6×
  6. 5Expanding Market Share of Blood Collection Tube Preparation Equipment5×
  7. 6Rolling Out a Global Business Strategy5×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Techno Medica yet. It last moved in the Share Issuance and Disposal of 2026-07-01: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.